Schedule a Consultation
(716) 839-3638
Hormone replacement therapy and venous thromboembolism - Vein Treatment Center and Dr Karamanoukian
Friday, August 16, 2013



Superficial vein thrombosis, deep vein thrombosis and venous thromboembolism and pulmonary embolism are common disorders with an incidence of 1 to 2 per 1000 person years among adults.  The incidence of deep vein thrombosis and venous thromboembolism increases with age, and men compared with women, in African-Americans compared with whites and obese versus non obese ndividuals.


Venous thromboembolism is generally not associated with other classic atherogenic risk factors.  It is well known that postmenopausal hormone replacement therapy, such as estrogen with or without progesterone and selective estrogen receptor modulators such as tamoxifen and raloxifene are associated with 2 to 3 fold increased risk of venous thromboembolism.


The women's health initiative estrogen progestin trial reported that 2.11 fold increased risk of venous thromboembolism among 16,608 women randomized to combined estrogen plus progestin therapy versus placebo.  Results from randomized clinical trials of estrogen plus progestin in healthy postmenopausal women has further shown an increased risk of thromboembolism and deep vein thrombosis.


For more information about hormone replacement therapy and the risk of venous thromboembolism contact a hematologist who specializes in blood clotting disorders (thrombophilia) or talk to your gynecologist or vein specialist.  Dr. Hratch Karamanoukian can be contacted at the Vein Treatment Center at or or by calling 716-839-3638. and are partners with


© 2012 Vein Guide, Inc. All rights reserved.